The development of EGFR molecular imaging and gene mutation in non-small cell lung cancer
- Author:
- No author available
- Journal Title:
- Chinese Journal of Nuclear Medicine and Molecular Imaging
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.2095-2848.2012.05.020
- Key Word:
- 癌,非小细胞肺;受体,表皮生长因子-尿抑胃素;基因;突变;体层摄影术,发射型计算机;Carcinoma,non-small cell lung;Receptors,epidemal growth factor-urogastrone;Genes;Mutation;Tomography,emission-computed
Abstract： In vivo epidermal growth factor receptor (EGFR) imaging has great potential to affect patient-specific treatment for NSCLC,applying a targeted therapy,and measuring molecular-specific effects of treatment.New PET/CT radiotracers,such as N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy]quinazolin-4-amine (ZD6476),five 4-(anilino) quinazoline derivatives (ML01) and 4-[(3-iodophenyl) amino]-7-(2-[2-{ 2-(2-[2-{ 2-([18F]fluoroethoxy)-ethoxy {-ethoxy]-ethoxy)-ethoxy}-ethoxy]-quinazoline-6-yl-acrylamide) ([18F]F-PEG6-IPQA) are now available.But,11C labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035) is the only PET/CT radiotracer used for human clinical evaluation,primarily for EGFR imaging.Finally,the most important aspect of successful imaging is the identification and characterization of EGFR at the cellular or sub-cellular level with high specificity for the target.Considering the need for further development of such PET/CT tracers,EGFR molecular imaging will be presented along with an important examination of the progression that has been made thus far in the field.
- [1]WANG Hui,YU Jin-ming,YANG Guo-ren,etc.Further characterization of the epidermal growth factor receptor ligand 11C-PD153035[J].2007,(11).
- [2]Tong W,Alauddin MM,Volgin A,etc.Radiosynthesis and initial in vitro evaluation of (18F)F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.[J].2011,13(5).
- [3]Yu J,Yang G,Sun X,etc.Assessment of (11)C-labeled-4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.[J].2007,98(9).
- [4]Jakobsen S,Nexo E,Sorensen BS,etc.Positron emission tomography (PET) imaging with (11C)-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.[J].2009,69(3).
- [5]McShane LM,Giaccone G,Wakelee HA,etc.American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy.[J].2011,29(15).
- [6]Gelovani JG.Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography.[J].2008,27(4).
- [7]Maemondo,M.,Inoue,A.,Kobayashi,K.,etc.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].2010,362(25).
- [8]Ferl GZ,Weber WA,Dubinett SM,etc.Evaluation of ((18)F)gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.[J].2008,35(6).
- [9]Kunstler JU,Bourkoula A,Santos IC,etc.Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a Tc-99m biomarker for EGFR-TK imaging[J].2008,0(24).
- [10]Mishani E,Hagooly A.Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer.[J].2009,50(8).
- [11]Abourbeh G,Mishani E.Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR).[J].2007,7(18).
- [12]Zhou C,Wu YL,Chen G,etc.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.[J].2011,12(8).
- [13]Toyohara J,Yanamoto K,Koike S,etc.(11C)gefitinib ((11c)Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.[J].2010,12(2).
- [14]Zheng QH,Gao M,Miller KD,etc.Synthesis of (11C)Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.[J].2006,16(15).